FENC Form 144 Notice — 1,775 Shares to Trade on NASDAQ 10/10/2025
Rhea-AI Filing Summary
Fennec Pharmaceuticals (FENC) filed a Form 144 notifying a proposed sale of 1,775 common shares with an aggregate market value of $16,401.00. The shares are scheduled for sale approximately on 10/10/2025 on NASDAQ. The filing shows the shares were acquired the same day, 10/10/2025, by stock option exercise from the issuer and paid in cash. There were 27,831,698 shares outstanding noted for the class. No securities were reported sold in the prior three months. The filer affirms they are not aware of undisclosed material adverse information and the notice contains the standard attestation language regarding trading plans and criminal penalties for false statements.
Positive
- Full disclosure of proposed sale details including broker, share count, value, and planned sale date
- Acquisition method transparently stated as a stock option exercise with cash payment on 10/10/2025
- No prior sales reported in the past three months for the selling person
Negative
- None.
Insights
Small post‑exercise sale planned by an insider via market broker.
The notice records a proposed open‑market sale of $16,401.00 for 1,775 shares to be executed through Morgan Stanley Smith Barney LLC on 10/10/2025. The shares were acquired by a stock option exercise and paid in cash on the same date, which indicates an immediate post‑exercise disposition rather than a long‑term transfer.
This transaction size represents a small fraction of the class base (27,831,698 outstanding), so it is unlikely to be price‑moving alone. Monitor trade execution on the listed exchange around 10/10/2025 for any clustering with other insider sales that could be material.
Filing follows Rule 144 disclosure and includes standard attestation.
The form includes the required representation that the seller is unaware of any undisclosed material adverse information and notes the possibility of a Rule 10b5‑1 trading plan if applicable. It names the executing broker and furnishes acquisition details (exercise from the issuer, cash payment).
From a compliance perspective, the clear dating of acquisition and planned sale simplifies rule‑144 eligibility review. If a trading plan or instruction date exists, it should be noted to confirm affirmative safe‑harbor timing.